<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Zhihong Cai | Chaochen Wang - Be Ambitious</title>
    <link>https://wangcc.me/authors/zhihong-cai/</link>
      <atom:link href="https://wangcc.me/authors/zhihong-cai/index.xml" rel="self" type="application/rss+xml" />
    <description>Zhihong Cai</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>© 2017-2025 Chaochen Wang | 王超辰</copyright><lastBuildDate>Sun, 10 Mar 2024 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://wangcc.me/img/icon-192.png</url>
      <title>Zhihong Cai</title>
      <link>https://wangcc.me/authors/zhihong-cai/</link>
    </image>
    
    <item>
      <title>Real-world Evidence of Skin Disorder-related Events Management in Patients with Lung Cancer Prescribed the RELAY Regimen (Erlotinib Plus Ramucirumab) - A Retrospective Observational Study Using A Health Insurance Claims Database in Japan [Article in Japanese] 肺癌患者におけるRELAYレジメン(エルロチニブ&#43;ラムシルマブ)処方時の皮膚障害関連事象マネジメントの実態-日本のレセプトデータベースを用いた後ろ向き観察研究-</title>
      <link>https://wangcc.me/publication/journal-article/2024relay/</link>
      <pubDate>Sun, 10 Mar 2024 00:00:00 +0000</pubDate>
      <guid>https://wangcc.me/publication/journal-article/2024relay/</guid>
      <description>&lt;h2 id=&#34;abstract-要旨&#34;&gt;Abstract 要旨&lt;/h2&gt;
&lt;p&gt;&lt;strong&gt;背景：&lt;/strong&gt; RELAYレジメン（エルロチニブ＋ラムシルマブ）は，EGFR遺伝子変異陽性の切除不能な進行・再発非小細胞肺癌治療に用いられるが，皮膚障害の発現が懸念される。&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;方法：&lt;/strong&gt; MDVデータベースを用いて，RELAYレジメン治療を受けた患者の特徴，テトラサイクリン系またはマクロライド系抗菌薬（以下，抗菌薬）の予防投与の有無，保湿薬やステロイド外用薬の処方状況を調査し，抗菌薬の予防投与の有無とRELAYレジメン開始後新たにレセプトに記録された皮膚障害関連事象との関連をロジスティック回帰モデルで分析した。&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;結果：&lt;/strong&gt; 研究対象227名中，抗菌薬の予防投与群は67名（29.5％）で，主にテトラサイクリン系抗菌薬が処方されていた。予防投与群でRELAYレジメン開始前からの保湿薬の処方割合は高く，開始後新たに記録されたざ瘡様皮疹，皮膚乾燥，および皮膚炎の割合は低かった。保湿薬・ステロイド外用薬の有無等を因子に含む多変量モデルで，抗菌薬の予防投与なしに対する予防投与ありでのざ瘡様皮疹のオッズ比は有意に1を下回った。&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;結論：&lt;/strong&gt; 抗菌薬の予防投与はRELAYレジメン治療に伴うざ瘡様皮疹の発現抑制に貢献すると考えられた。&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Background：&lt;/strong&gt; The RELAY regimen（erlotinib＋ramucirumab）is used for the　treatment of EGFR-mutated, unresectable, advanced or recurrent non-small cell lung　cancer；however, the onset of skin disorders is concerning.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Methods：&lt;/strong&gt; Using the Medical Data Vision database, we described the characteristics　of patients treated with the RELAY regimen, including prior use of tetracycline or macrolide antibiotics, and the prescription status of moisturizing agents and topical steroids. Furthermore, we used logistic regression models to analyze the association between prior antibiotic use and skin disorder-related events newly recorded in health insurance claims after the start of the RELAY regimen.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Results：&lt;/strong&gt; Of 227 patients, 67 patients（29.5％）had received prior antibiotics, primarily tetracyclines. In patients with prior antibiotic use, the prescription rate of moisturizers before the start of the RELAY regimen was high, and the rates of newly recorded dermatitis acneiform, dry skin, and dermatitis after the start of the RELAY regimen were low. In a multivariate model that includes factors such as the presence or absence of moisturizers or topical steroids, the odds ratio of dermatitis acneiform with prior antibiotic use was significantly lower than 1 when no prior antibiotic use was set as the reference.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Conclusions：&lt;/strong&gt; Prior antibiotic use may contribute to the suppression of dermatitis acneiform in patients with lung cancer treated with the RELAY regimen.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Key words：&lt;/strong&gt; EGFR inhibitor, prior antibiotic use, non-small cell lung cancer, ramucirumab, health insurance claims database&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study</title>
      <link>https://wangcc.me/publication/journal-article/cllmdv/</link>
      <pubDate>Tue, 26 Dec 2023 00:00:00 +0000</pubDate>
      <guid>https://wangcc.me/publication/journal-article/cllmdv/</guid>
      <description>&lt;h2 id=&#34;abstract&#34;&gt;Abstract&lt;/h2&gt;
&lt;p&gt;Standard treatment has not been established for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after discontinuation of covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy. This retrospective, administrative database (Medical Data Vision) study described the patient characteristics, treatment patterns, and factors associated with receiving post-first-cBTKi treatment in Japanese patients with CLL/SLL. Patients aged ≥18 years with confirmed CLL/SLL diagnosis and treated with anti-neoplastic drugs indicated for CLL/SLL between March 2013 and February 2022 were included. Patient characteristics at baseline (first line), first cBTKi exposure (first-cBTKi), post-first-cBTKi treatment received, and the treatment sequence of CLL drugs received first line through third line, were described. Time-to-event analyses used the Kaplan-Meier method. Multivariable logistic regression analysis was used to explore factors associated with receiving post-first-cBTKi treatment among patients who discontinued first-cBTKi treatment. Among 2,424 eligible patients (median age: 72.0 years, 61.9% male), 450 (18.6%) received cBTKi in any treatment line. Among patients treated with cBTKi, 273 (60.7%) discontinued treatment; 56.0% of them (n = 153/273) received subsequent treatment. Median duration of post-first-cBTKi treatment was 2.2 months (95% confidence interval [CI]: 1.8, 3.5). The most common regimens post-first-cBTKi were cBTKi therapy (47.7%), bendamustine-based therapy (17.0%), and venetoclax-based therapy (13.1%). Patients aged &amp;lt;75 years (odds ratio [OR] [95% CI]: 2.0 [1.2, 3.4]) and those who did not receive blood transfusion during cBTKi treatment (OR [95% CI]: 2.3 [1.3, 4.1]) were more likely to receive post-first-cBTKi treatment. In conclusion, Japanese patients with CLL/SLL received various treatments for short duration after first-cBTKi discontinuation.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Keywords&lt;/strong&gt;: cBTKi; chronic lymphocytic leukemia; small lymphocytic lymphoma; time to treatment discontinuation; treatment patterns.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study</title>
      <link>https://wangcc.me/publication/journal-article/il17trtsurvival/</link>
      <pubDate>Tue, 04 Jul 2023 00:00:00 +0000</pubDate>
      <guid>https://wangcc.me/publication/journal-article/il17trtsurvival/</guid>
      <description>&lt;h2 id=&#34;abstract&#34;&gt;Abstract&lt;/h2&gt;
&lt;p&gt;&lt;strong&gt;Background and objective&lt;/strong&gt;: Real-world evidence on persistence of interleukin-17 inhibitors (IL-17i) as a drug class among Japanese patients with psoriasis is lacking. Hence, we aimed to describe persistence rates of IL-17is among patients with psoriasis including psoriasis vulgaris (PsO), psoriatic arthritis (PsA), and generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP) in Japan.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Methods&lt;/strong&gt;: We analyzed claims data from the Medical Data Vision database. Patients ≥15 years old with a psoriasis diagnosis and an IL-17i prescription between November 2016 and August 2020 were included and followed through August 2021. Persistence rates of the IL-17i class among patients with psoriasis and its subtypes (PsO, PsA, and GPP or EP), and persistence rates of ixekizumab, secukinumab, or brodalumab among patients with PsO or PsA were analyzed using Kaplan-Meier method. Analyses were conducted in the bio-naïve and bio-experienced subgroups.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Results&lt;/strong&gt;: The IL-17i class had &amp;gt;50% persistence rates up to 36 months among patients with psoriasis and its subtypes (PsO, PsA, and GPP or EP). 36-Month persistence rates for ixekizumab, secukinumab, and brodalumab were 46.2% to 57.7% in patients with PsO and 43.0% to 48.4% in patients with PsA. Across analyses, bio-naïve patients demonstrated similar or greater persistence rates than bio-experienced patients.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Conclusion&lt;/strong&gt;: IL-17is&amp;rsquo; persistence rates over 36 months were &amp;gt;50% among patients with psoriasis and its subtypes (PsO, PsA, and GPP or EP) in Japan.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Keywords&lt;/strong&gt;: IL-17 inhibitor; Psoriasis vulgaris; erythrodermic psoriasis; generalized pustular psoriasis; psoriatic arthritis; treatment persistence.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
